Company announces positive top-line results from Contessa Phase 3 study of Tesetaxel in patients with metastatic breast cancer

In this RCT (n=685), tesetaxel (an orally administered taxane) plus a reduced dose of capecitabine significantly improved progression-free survival (PFS) vs. the higher approved dose of capecitabine alone (median PFS 9.8 months vs. 6.9, respectively; hazard ratio =0.716; p=0.003)


Biospace Inc.